Overview |
bs-10176R |
PRAS40 Polyclonal Antibody |
WB, ELISA, IHC-P, IHC-F, IF(IHC-P), IF(IHC-F), IF(ICC), ICC |
Human |
Mouse, Rat, Cow, Sheep, Pig, Horse |
Specifications |
Unconjugated |
Rabbit |
KLH conjugated synthetic peptide derived from human PRAS40 |
161-256/256 |
Polyclonal |
IgG |
1ug/ul |
Purified by Protein A. |
0.01M TBS(pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
Shipped at 4°C. Store at -20°C for one year. Avoid repeated freeze/thaw cycles. |
Target |
84335 |
Q96B36 |
Cytoplasm |
AKT1 substrate 1 (proline rich); AKT1 substrate 1; AKT1-S1; AKT1S-1; AKT1S 1; AKT1S1; Lobe; PRAS 40; PRAS-40; PRAS40; Proline rich akt substrate; 40 kDa proline rich AKT substrate; 40 kDa proline-rich AKT substrate; AKT1 S1; AKT1 substrate 1; AKTS1_HUMAN; MGC2865; PRAS40; Proline rich Akt substrate 40 kDa; Proline-rich AKT1 substrate 1. |
Proline Rich Akt Substrate (PRAS40) is a 40 kDa substrate of Akt. Akt and PRAS40 can be found in the phosphoinositide 3 kinase (PI3K) pathway, which plays a role in glucose uptake, cell growth, and apoptosis inhibition. PRAS40 is a 14-3-3 binding protein that reacts with insulin, but whose precise function is not yet known. It may bind SH3 and WW domain containing proteins resulting in a change of function. Activated Akt phosphorylates PRAS40 on threonine 246. Mutation of PRAS40 threonine 246 has been shown to be apoptotic. |
Application Dilution |
WB |
1:300-5000 |
ELISA |
1:500-1000 |
IHC-P |
1:200-400 |
IHC-F |
1:100-500 |
IF(IHC-P) |
1:50-200 |
IF(IHC-F) |
1:50-200 |
IF(ICC) |
1:50-200 |
ICC |
1:100-500 |